Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.53 |
| ▸ | AXL | P30530 | 6/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | YES1 | P07947 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CSK | P41240 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264049 | 0.92 | AXL (0.58) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL264327 | 0.88 | AXL (0.62) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL264602 | 0.85 | KCNH2 (0.52) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL265091 | 0.85 | AXL (0.64) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL264617 | 0.85 | AXL (0.57) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL265396 | 0.85 | AXL (0.51) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL263711 | 0.85 | AXL (0.57) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL263807 | 0.85 | AXL (0.59) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL266734 | 0.84 | SRC (0.49) | SRCAXLKDRYES1PDGFRB | |
| SCHEMBL264880 | 0.84 | AXL (0.52) | SRCAXLKDRYES1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | SRC 80/4885AXL 267/4885KDR 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.